Bonilla OcampoDAPaipillaAFMarnEVargas-MolinaSPetroJLPrez-IdrragaA
Designing HDAC-PROTACs: lessons learned so far
Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets
104.1 The caregiver experience in amyotrophic lateral sclerosis (ALS): a mixed-methods study to examine the lived experience of caring for people living with ALS and to develop a novel ALS Caregiver Impact Questionnaire (ALS-CIQ) William Nowell 1 , Nadine McGale 2 , Oren Levy 1 , Sarah Wilding 2 , Phoebe Heinrich 2 , Nick Patel 1 , Jinsy Andrews 3 , Diana Rofail 1 1 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA, 2 Modus Outcomes, Cambridge, Massachusetts, USA, 3 Department of Neurology, Colombia University, New York, USA Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :104.1 Aims This study aimed to develop a conceptualization of the personal experience of caregivers of people living with amyotrophic lateral sclerosis (pALS), and a novel instrument to assess caregiver impact
The medication that once cost me $25 per month would now cost in the thousands if I bought it from my pharmacy, or $449 if I purchased it directly from the manufacturer, Eli Lilly
